Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Other Non Operating Income (2018 - 2026)

10x Genomics' Other Non Operating Income history spans 8 years, with the latest figure at -$2.5 million for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 16.56% to -$2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 149.83% increase, with the full-year FY2025 number at $1.0 million, up 149.83% from a year prior.
  • Other Non Operating Income hit -$2.5 million in Q4 2025 for 10x Genomics, down from -$1.2 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for TXG hit a ceiling of $4.0 million in Q4 2022 and a floor of -$3.0 million in Q4 2024.
  • Historically, Other Non Operating Income has averaged -$116150.0 across 5 years, with a median of -$664000.0 in 2021.
  • The widest YoY moves for Other Non Operating Income: up 79800.0% in 2022, down 453.74% in 2022.
  • Tracing TXG's Other Non Operating Income over 5 years: stood at $5000.0 in 2021, then skyrocketed by 79800.0% to $4.0 million in 2022, then fell by 0.33% to $4.0 million in 2023, then tumbled by 176.57% to -$3.0 million in 2024, then rose by 16.56% to -$2.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for TXG at -$2.5 million in Q4 2025, -$1.2 million in Q3 2025, and $2.6 million in Q2 2025.